Friday, 11th of March 2011 |
Intradermal vaccine delivery looks like a highly technical topic, but it might be the Next Big Thing in vaccination. If solid evidence is available that fractional doses of certain parenterally administered vaccines can be given intradermally without significant differences in seroconversion rates, then – once licensing and other hurdles were overcome – the door would be open to lower costs per fully immunized child. This would be a refreshing change from the last decade, where vaccine costs per fully vaccinated child quintupled in some GAVI beneficiary countries.
JK Hickling,a KR Jones,a M Friede,b D Zehrung,c D Chenc & D
Kristensenc
a Working in Tandem, Cambridge, England.
b Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva,
Switzerland.
c Program for Appropriate Technology in Health (PATH), PO Box 900922, Seattle, WA, 98109,
United States of America.
Correspondence to Darin Zehrung (e-mail: dzehrung@path.org)
(Submitted: 5 May 2010 – Revised version received: 1 November 2010 – Accepted: 2 November
2010 – Published online:21 January 2010)
Abstract
Delivery of vaccine antigens to the dermis and/or epidermis of human skin (i.e. intradermal delivery) might be more efficient than injection into the muscle or subcutaneous tissue, thereby reducing the volumes of antigen. This is known as dose-sparing and has been demonstrated in clinical trials with some, but not all, vaccines. Dose-sparing could be beneficial to immunization programmes by potentially reducing the costs of purchase, distribution and storage of vaccines; increasing vaccine availability and effectiveness. The data obtained with intradermal delivery of some vaccines are encouraging and warrant further study and development; however significant gaps in knowledge and operational challenges such as reformulation, optimizing vaccine presentation and development of novel devices to aid intradermal vaccine delivery need to be addressed. Modelling of the costs and potential savings resulting from intradermal delivery should be done to provide realistic expectations of the potential benefits and to support cases for investment. Implementation and uptake of intradermal vaccine delivery requires further research and development, which depends upon collaboration between multiple stakeholders in the field of vaccination.
Introduction
Most vaccines are delivered by the intramuscular or subcutaneous routes using a needle and syringe; the intradermal route is only widely used for the administration of Bacille Calmette-Guérin and rabies vaccines. However there is renewed interest in intradermal vaccine delivery, driven by the fact that the dermis and epidermis of human skin are rich in antigen-presenting cells, suggesting that delivery of vaccines to these layers, rather than to muscle or subcutaneous tissue, should be more efficient and induce protective immune responses with smaller amounts of vaccine antigen.1
Clinical trials investigating intradermal delivery and its potential for dose-sparing have been conducted with several different vaccines, with variable results. These have been reviewed in a recent report from the Program for Appropriate Technology in Health (PATH) and the World Health Organization (WHO).2 For some vaccines, there has been a clear demonstration of dose-sparing by intradermal delivery; however, there are several
gaps in knowledge as well as developmental and operational challenges to overcome if the benefits of using intradermal delivery are to be fully realized.
Dose-sparing arising from intradermal delivery of vaccines could be beneficial to immunization programmes, particularly in resource-poor settings, by potentially reducing the per-injection cost (including transport and storage) of vaccines because more doses might be obtained from the existing vaccine presentation.
Dose-sparing might also “stretch” the availability of vaccines in cases where supply is limited by manufacturing capacity. This is probably most relevant for pandemic influenza vaccines where global production capacity limits access to a vaccine at the start of a pandemic.3 In 2009, H1N1 vaccine was not available in most low-income countries until 8 months after WHO’s declaration of the influenza pandemic.4
Other vaccines with potential supply constraints include yellow fever and inactivated poliovirus vaccines.5,6 The level of demand for inactivated poliovirus vaccine in the period following eradication of wild-type polioviruses and the end of the use of oral poliovirus vaccines is uncertain, but modelling suggests that there could be a “demand spike” and supply shortage of inactivated poliovirus vaccine during this period.6
New delivery devices
New devices for easier, more reliable intradermal delivery as alternatives to the currently used Mantoux technique are being developed.2,7 Some of the devices such as disposablesyringe jet injectors are needle-free and could therefore reduce or eliminate needlestick injuries and the costs associated with their treatment, estimated at US$ 535 million per year worldwide.8 Other intradermal delivery devices such as microneedle patches are
likely to occupy less volume than vials or prefilled syringes, thereby reducing demands on cold-chain capacity.
Current clinical research
The recent PATH and WHO report reviewed more than 90 clinical trials of intradermal delivery with vaccines against 11 diseases.2 For some vaccines, notably influenza and rabies vaccines, intradermal delivery of reduced doses resulted in equivalent immune responses to the standard dose delivered by the standard route. Data from trials with hepatitis B vaccine were more variable, but also regarded as encouraging.9 Promising data demonstrating dose-sparing have also been obtained with other vaccines including inactivated poliovirus, yellow fever and hepatitis A vaccines.2
Two recently published trials of intradermal delivery of reduced (20%) doses of inactivated poliovirus vaccines have reported contrasting results: one trial found that reduced intradermal doses administered to infants aged 2, 4 and 6 months induced similar rates of seroconversion but lower mean antibody titres, compared with intramuscular injection12; however a similar study administered the vaccine at 6, 10 and 14 weeks of age and observed inferior seroconversion rates with reduced intradermal doses.13 Trials of intradermal immunization with seasonal and pandemic influenza
vaccines have also been reported in the past year. Dose-sparing was not observed with a nonadjuvanted, subvirion H5N1 vaccine,14 whereas a 60% intradermal dose of a trivalent seasonal flu vaccine resulted in similar immunogenicity as a standard dose delivered intramuscularly.15
Some rabies vaccines are already delivered using intradermal regimens using needle and syringe.16,17 Recently, a new intradermal injection device (Soluvia,™ Becton Dickinson, Franklin Lakes, NJ, United States of America) was evaluated for intradermal delivery of rabies vaccine; intradermal administration of a 25% dose of rabies vaccine resulted in equivalent antibody titres and seroconversion rates to the full dose delivered
Recent vaccine approvals
A new presentation of a split, trivalent seasonal influenza vaccine, Intanza® (Sanofi pasteur, Lyon, France) has been developed for intradermal immunization. The vaccine is delivered using the Soluvia device, a prefilled syringe with a single needle that is 1.5 mm in length.19,20 Immune responses equivalent to those induced by the standard regimen can be achieved using this device and 60% of the standard dose of influenza vaccine.21,22 A
reduced-dose formulation (9-μg haemagglutinin rather than the standard 15-μg haemagglutinin) for use in healthy adults and a 15-μg haemagglutinin formulation for intradermal delivery in adults aged ³ 60 years have been approved in Australia, Europe and New Zealand.23–25
Despite the number of clinical trials conducted, there is still a lack of certainty whether intradermal delivery offers significant immunological advantages compared with intramuscular or subcutaneous delivery. Very few trials have compared equivalent doses (amounts of antigen) delivered by the different routes and, as such, do not permit direct comparison of relative immunological efficacy of the different methods; the recent studies with modified vaccinia Ankara are notable exceptions.10,11 Most trials have aimed only to determine whether reduced intradermal doses were able to induce a sufficient or non-inferior immune response compared with the standard regimen. In these cases it is possible that a reduced dose delivered by the standard route would also have resulted in an equivalent immune response, as has been reported with some influenza vaccines.26,27 Furthermore, the majority of dose-sparing trials have for reasons of practical simplicity delivered 10% or 20% of the standard dose intradermally. Finer dose-titrations such as
those performed with influenza vaccines have shown that less-dramatic reductions in dose, such as a 40% reduction, might be more realistic.22 To address these concerns, future studies should compare equivalent antigen doses given by the intradermal and standard route and, if possible, establish a dose–response relationship to determine whether any dose-sparing effect observed is simply due to using doses of antigen from the plateau-portion of the dose–response curve.
Which vaccines?
Live-attenuated vaccines have been successfully delivered intradermally and should be good candidates for intradermal delivery providing that appropriate formulations can be developed.2 Reduced doses of inactivated whole-virion vaccines, such as rabies and inactivated poliovirus vaccines, have also shown satisfactory immunogenicity when delivered intradermally. Inactivated whole-virion influenza vaccines might also be suitable because they have intrinsic immune-stimulating sequences, which might avoid the need for additional adjuvants.28 There are no published clinical data regarding intradermal delivery of polysaccharide conjugate vaccines, which include meningococcal and pneumococcal conjugate vaccines, yet evaluation would be
worthwhile particularly because high cost has limited the introduction of pneumococcal conjugate vaccines in some low-resource countries.29
Vaccines that contain aluminium-based or oil-in-water adjuvants are likely to have unacceptable local reactogenicity following intradermal administration. Clinical trials of intradermal delivery of vaccines formulated with these or novel adjuvants are needed.
Potential benefits
Realistic estimates of the cost savings that might be achieved by ID dose-sparing have not been established for most vaccines, especially those that might be relevant to routine immunization in low- and middle-resource countries. Cell-culture-produced rabies vaccines are expensive and are used in complex,
multi-dose schedules for post-exposure prophylaxis. A limited number of cell-culturederived rabies vaccines and two intradermal immunization regimens are already recommended by WHO.16,17 The overall costs involved in administering post-exposure prophylaxis using intramuscular or intradermal regimens in different clinic settings in India have been compared.30 Although significant savings were achieved with intradermal regimens, reducing the dose to 20% of the intramuscular dose did not reduce the overall costs by 80%, instead savings of 15–38% were obtained, depending on the
setting. Intradermal regimens that used 10% rather than 20% of the standard dose resulted in a further reduction in costs of only 9–15%. Furthermore, the estimates did not include costs resulting from vaccine wastage, which were expected to be higher in intradermal regimens.
A major benefit of changing to needle-free devices is a reduction in the direct health-care and societal costs resulting from needlestick injuries, although this is difficult to quantify in financial terms.8,31 A reduction in the use of sharps and their associated costs could also be achieved, possibly more easily, by using needle-free delivery devices such as disposable-syringe jet injectors, without changing the route or dose of vaccine
The incremental costs associated with changing some routine childhood accinations in Brazil, India and South Africa to intradermal delivery of reduced (20%) doses have been modelled.32 For India and South Africa, the model indicated that intradermal delivery of reduced doses of hepatitis B vaccine using disposable-syringe jet injectors would increase the overall costs per fully-immunized child by US$ 0.45 and by US$ 0.76, respectively; hepatitis B vaccine is only one of five or six infant vaccines routinely administered in these two countries. In contrast, in Brazil, the model indicated
that intradermal reduced doses of hepatitis B and yellow fever vaccines would reduce overall costs per fully-immunized child by US$ 0.11. Although antigen content of the vaccines delivered intradermally was reduced by 80%, the model showed that prices w re only reduced by 20%. The model did not include costs associated with treatment of bloodborne infections transmitted by sharps.
Challenges
Changing the delivery route and dose for a vaccine is not a straightforward task, and several challenges and operational issues need to be addressed.
Demonstration of efficacy
The applicability and benefits of intradermal administration will vary among vaccines; it cannot be assumed that reduced intradermal doses will be efficacious in all cases. Even when there is dose-sparing, it might not be with a dose as low as 20% or 10% of the standard dose. The degree of dose-sparing that can be achieved will need to be determined for each vaccine in non-inferiority trials. It will also be important to maintain a “margin of safety” to ensure adequate immunogenicity across the whole target population and to ensure the potency of the reduced dose is sufficient to induce protection at the end of the vaccine’s shelf life.
Reformulation
Intradermal doses of 20% of a standard 0.5 ml dose or 10% of a 1.0 ml dose might not require reformulation; 0.1 ml of the existing formulation could easily be administered, as is the usual practice in clinical trials of intradermal delivery. If more antigen per dose is required, then the vaccine will need to be concentrated so that it can be delivered in the smaller volume. In the development of Intanza®, which contains 60% of the standard amount of antigen in 20% of the volume, there were challenges filling the device with a small volume as well as adjusting vaccine concentration and viscosity.34Even if there is no need to adjust the concentration of the vaccine, it might be necess ry to incorporate a preservative into the formulation if dose-sparing means that more than one dose can be obtained per vial.
Vaccine presentation
One consequence of delivering a smaller volume per dose is that a single-dose vial presentation would effectively become a multi-dose vial, yielding perhaps 5 or 10 intradermal doses. Liquid vaccines with multi-dose vial presentations can contain preservatives so that unused vaccine can be stored more safely beyond the end of an immunization session.35 Single-dose vials do not typically contain thiomersal or other preservatives. If dose-sparing allows multiple doses to be drawn from preservative-free vaccines in single-dose vials, unused vaccine would have to be discarded at the end of the
immunization session. Computer modelling has shown that matching the number of doses per vial with the immunization session’s size has a significant economic impact in terms of minimizing vaccine wastage as well as supply, storage and disposal costs.36 For some vaccines and settings, fewer than five doses per vial would be the most cost-effective option. Therefore, alternative, smaller-volume presentations might be required, otherwise
intradermal delivery might not yield the expected cost savings in settings where immunization session-sizes are small.
Regulatory issues
Intradermal delivery of fractional doses of an existing vaccine formulation intended for subcutaneous/intramuscular injection would have to be undertaken on an “off-label” basis. A licensing amendment between the relevant national regulatory authority and the vaccine producer would be needed to authorize official “on-label” use of fractional doses.37 Alternatively, marketing approval for the new intradermal formulation and
For many existing vaccines, there might not be a sufficiently strong commercial incentive for manufacturers to undertake the expensive processes of reformulation, production of new presentations and application for marketing authorizations for a new delivery route. Novel vaccines might, therefore, be more likely candidates for intradermal delivery. This route should be evaluated early in research and development to avoid expensive retesting and redevelopment at a later stage. Unless there are strong drivers to use the intradermal route, vaccine manufacturers are likely to continue to use standard
presentations and routes of delivery even for new vaccines, thereby reducing risk from the development process.
Novel devices for simple, reliable and reproducible intradermal delivery of vaccines will be needed if this route is to be widely used. There are several different types of intradermal delivery devices in development.1,2,7 However they cannot be developed in isolation; the device inventors require access to vaccines and collaboration with vaccine manufacturers to enable development, testing and approval of device/vaccine combinations.
In the shorter term, delivery technologies could include simple adapters fitted to existing needles and syringes to control the depth and angle of delivery, syringe-mounted arrays of hollow microneedles and needle-free disposable-syringe jet injectors.2 Each of these approaches is compatible with existing liquid and lyophilized formulations and presentations and so should be simpler to introduce into immunization programmes than some other technologies.
Conclusion
Data from clinical trials indicate that intradermal delivery of reduced doses of some, although not all, vaccines results in equivalent immune responses to the standard regimen. An increasing number of trials are producing data that support dose-sparing. However, there are significant operational challenges, such as reformulation, changing from a single- to a multiple-dose presentation, development of intradermal delivery
devices and training health workers. Economic studies and modelling exercises have shown that cost savings should be achievable with intradermal immunization with some vaccines. These analyses are needed to help guide and support development and implementation of intradermal vaccine delivery as well as provide an indication of potential savings.
Research and development in all of these disciplines is required if the promise of intradermal delivery is to be realized; this will require collaboration between academic and clinical researchers, vaccine manufacturers, device developers, regulatory authorities, national immunization programmes and nongovernmental global health organizations. A careful evaluation of all aspects of this route of delivery for vaccines should continue to
be a priority for global public health.
Acknowledgements
We thank Courtney Jarrahian and Kristina Lorensen for reviewing the manuscript and
Emily Griswold for proofreading.
Funding:
Work on this article by PATH staff members and consultants was supported by funding
from the Bill & Melinda Gates Foundation. The authors had full control of all primary
data.
Competing interests:
None declared.
References
1. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery
systems transform vaccine administration? Vaccine 2008;26:3197-208.
PMID:18486285 doi:10.1016/j.vaccine.2008.03.095
2. Intradermal delivery of vaccines: a review of the literature and potential for
development for use in low- and middle-income countries. Seattle:
Program for Appropriate Technology in Health (PATH); 2009. Available
from: http://www.path.org/files/TS_opt_idd_review.pdf [accessed 16
December 2010].
3. Kieny MP, Costa A, Hombach J, Carrasco P, Pervikov Y, Salisbury D, et al. A
global pandemic influenza vaccine action plan. Vaccine 2006;24:6367-70.
PMID:17240560 doi:10.1016/j.vaccine.2006.07.021
4. Partridge J, Kieny MP. Global production of seasonal and pandemic (H1N1)
influenza vaccines in 2009-2010 and comparison with previous estimates
and global action plan targets. Vaccine 2010;28:4709-12. PMID:20488262
doi:10.1016/j.vaccine.2010.04.083
5. Yellow fever initiative: providing an opportunity of a lifetime. Geneva: World
Health Organization; 2010. Available from:
http://www.who.int/csr/disease/yellowfev/YFIbrochure.pdf [accessed 16
December 2010].
6. Oliver Wyman Inc. Global post-eradication IPV supply and demand
assessment: integrated findings. Seattle: Bill & Melinda Gates Foundation;
2009. Available from:
http://www.polioeradication.org/content/general/March%202009%20OW%
20IPV%20Effort%20Report.pdf [accessed 16 December 2010].
7. Weniger BG, Papania MJ. Alternative vaccine delivery methods. In: Plotkin
SA, Orenstein WA, Offit PA, eds. Vaccines, 5th ed. Amsterdam: Elsevier;
2008:1357-92.
8. Miller MA, Pisani E. The cost of unsafe injections. Bull World Health Organ
1999;77:808-11. PMID:10593028
9. Sangaré L, Manhart L, Zehrung D, Wang CC. Intradermal hepatitis B
vaccination: a systematic review and meta-analysis. Vaccine
2009;27:1777-86. PMID:19200451 doi:10.1016/j.vaccine.2009.01.043
10. Wilck MB, Seaman MS, Baden LR, Walsh SR, Grandpre LE, Devoy C, et al.
Safety and immunogenicity of modified vaccinia Ankara (ACAM3000):
effect of dose and route of administration. J Infect Dis 2010;201:1361-70.
PMID:20350191 doi:10.1086/651561
11. Seaman MS, Wilck MB, Baden LR, Walsh SR, Grandpre LE, Devoy C, et al.
Effect of vaccination with modified vaccinia Ankara (ACAM3000) on
subsequent challenge with Dryvax. J Infect Dis 2010;201:1353-60.
PMID:20350190 doi:10.1086/651560
12. Mohammed AJ, AlAwaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban MMA,
et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J
Med 2010;362:2351-9. PMID:20573923 doi:10.1056/NEJMoa0909383
13. Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, Sarmiento L, et al.
Randomized controlled clinical trial of fractional doses of inactivated
poliovirus vaccine administered intradermally by needle-free device in
Cuba. J Infect Dis 2010;201:1344-52. PMID:20350164
doi:10.1086/651611
14. Patel SM, Atmar RL, El Sahly HM, Cate TR, Keitel WA. A phase I evaluation
of inactivated influenza A/H5N1 vaccine administered by the intradermal
or the intramuscular route. Vaccine 2010;28:3025-9. PMID:19931380
doi:10.1016/j.vaccine.2009.10.152
15. Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal
influenza vaccination in healthy older adults. Clin Infect Dis 2010;50:1331-
8. PMID:20377407 doi:10.1086/652144
16. WHO expert consultation on rabies (WHO technical report series 931).
Geneva: World Health Organization; 2005. Available from:
http://www.who.int/rabies/trs931_%2006_05.pdf [accessed 16 December
2010].
17. World Health Organization. Rabies vaccines. WHO position paper. Wkly
Epidemiol Rec 2007;82:425-35. PMID:18064757
18. Laurent PE, Bourhy H, Fantino M, Alchas P, Mikszta JA. Safety and efficacy
of novel dermal and epidermal microneedle delivery systems for rabies
vaccination in healthy adults. Vaccine 2010;28:5850-6. PMID:20600481
doi:10.1016/j.vaccine.2010.06.062
19. Alarcon JB, Hartley AW, Harvey NG, Mikszta JA. Preclinical evaluation of
microneedle technology for intradermal delivery of influenza vaccines. Clin
Vaccine Immunol 2007;14:375-81. PMID:17329444
doi:10.1128/CVI.00387-06
20. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, et al.
Evaluation of the clinical performance of a new intradermal vaccine
administration technique and associated delivery system. Vaccine
2007;25:8833-42. PMID:18023942 doi:10.1016/j.vaccine.2007.10.020
21. Arnou R, Eavis P, Pardo JDJ, Ambrozaitis A, Kazek M, Weber F.
Immunogenicity, large-scale safety and lot consistency of an intradermal
influenza vaccine in adults aged 18–60 years: Randomized, controlled,
phase III trial. Hum Vaccin 2010;6:346-54. PMID:20372053
doi:10.4161/hv.6.4.10961
22. Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, et
al. Intradermal influenza vaccination of healthy adults using a new
microinjection system: a 3-year randomised controlled safety and
immunogenicity trial. BMC Med 2009;7:13. PMID:19341446
doi:10.1186/1741-7015-7-13
23. Committee for Medical Products for Human Use. Summary of product
characteristics (Intanza 9microgram). Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000957/WC500033852.pdf [accessed 16
December 2010].
24. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek M, Weber F, et al.
Intradermal influenza vaccine for older adults: a randomized controlled
multicenter phase III study. Vaccine 2009;27:7304-12. PMID:19849996
doi:10.1016/j.vaccine.2009.10.033
25. Australian Drug Evaluation Committee. ADEC 262nd meeting resolutions;
resolution 9254. Commonwealth of Australia Gazette 2009;11. Available
from: http://www.tga.gov.au/docs/html/adec/adec0262.htm [accessed 16
December 2010].
26. Treanor J, Keitel W, Belshe R, Campbell J, Schiff G, Zangwill K, et al.
Evaluation of a single dose of half strength inactivated influenza vaccine in
healthy adults. Vaccine 2002;20:1099-105. PMID:11803070
doi:10.1016/S0264-410X(01)00440-6
27. Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, et al.
Comparative immunogenicity of trivalent influenza vaccine administered
by intradermal or intramuscular route in healthy adults. Vaccine
2007;25:6755-63. PMID:17692438 doi:10.1016/j.vaccine.2007.06.066
28. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, et al.
Superior immunogenicity of inactivated whole virus H5N1 influenza
vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog
2008;4:e1000138. PMID:18769719
29. World Health Organization. Worldwide progress in introducing pneumococcal
conjugate vaccine, 2000–2008. Wkly Epidemiol Rec 2008;83:388-92.
PMID:18949860
30. Goswami A, Plun-Favreau J, Nicoloyannis N, Sampath G, Siddiqui MN,
Zinsou J. The real cost of rabies post-exposure treatments. Vaccine
2005;23:2970-6. PMID:15811642 doi:10.1016/j.vaccine.2004.12.008
31. Ekwueme DU, Weniger BG, Chen RT. Model-based estimates of risks of
disease transmission and economic costs of seven injection devices in
sub-Saharan Africa. Bull World Health Organ 2002;80:859-70.
PMID:12481207
32. Griffiths UK, Santos AC, Nundy N, Jacoby E, Matthias D. Incremental costs
of introducing jet injection technology for delivery of routine childhood
vaccinations: Comparative analysis from Brazil, India and South Africa.
Vaccine 2010 Nov 27 [Epub ahead of print]. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/21115059 [accessed 16 December
2010].
33. Improving the affordability of inactivated poliovirus vaccines (IPV) for use in
low- and middle-income countries: an economic analysis of strategies to
reduce the cost of routine IPV immunization. Seattle: Program for
Appropriate Technology in Health (PATH); 2010. Available from:
http://www.path.org/publications/details.php?i=1809 [accessed 16
December 2010].
34. Picot V. Intradermal immunization: an alternative route for vaccine
administration. Articles as per sessions meeting report. Vaccine 2008;26
Suppl 9;S1-5. PMID:19268138 doi:10.1016/j.vaccine.2008.10.092
35. The use of opened multi-dose vials of vaccine in subsequent immunization
sessions. Geneva: World Health Organization; 2000. Available from:
http://www.who.int/vaccines-documents/DocsPDF99/www9924.pdf
[accessed 16 December 2010].
36. Lee BY, Norman BA, Assi T, Chen S, Bailey RR, Rajgopal J, et al. Single
versus multi-dose vaccine vials: an economic computational model.
Vaccine 2010;28:5292-300. PMID:20566395
doi:10.1016/j.vaccine.2010.05.048
37. Report of a meeting on priorities for pneumococcal and Haemophilus
influenzae type b (Hib) vaccine development, February 1999. Geneva:
World Health Organization; 2001. Available from:
http://www.who.int/vaccines-documents/DocsPDF01/www530.pdf
[accessed 16 December 2010].
38. Kim YC, Quan F, Compans RW, Kang S, Prausnitz MR. Formulation and
coating of microneedles with inactivated influenza virus to improve vaccine
stability and immunogenicity. J Control Release 2010;142:187-95.
PMID:19840825 doi:10.1016/j.jconrel.2009.10.013
39. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi
S, et al. Dissolving polymer microneedle patches for influenza vaccination.
Nat Med 2010;16:915-20. PMID:20639891 doi:10.1038/nm.2182 Available
from: http://www.ncbi.nlm.nih.gov/pubmed/20639891 [accessed 16
December 2010].
40. Fernando GJP, Chen X, Prow TW, Crichton ML, Fairmaid EJ, Roberts MS, et
al. Potent immunity to low doses of influenza vaccine by probabilistic
guided micro-targeted skin delivery in a mouse model. PLoS ONE
2010;5:e10266. PMID:20422002 doi:10.1371/journal.pone.0010266
--
To subscribe or unsubscribe from these Child Survival Updates, pls contact kidsurvival@gmail.com. If you unsubscribe, indicate from which E mail address you are receving these updates.
When subscribing, write from your most permanent E-mail address, not always that of your current employer.
Do not subscribe on behalf of friends or colleagues; forward updates to them for their decision.
Those wishing to read only malaria updates should subscribe at
kidsurvivalmalaria@gmail.com
Those wishing to read only vaccination updates should subscribe at kidsurvivalvaccination@gmail.com
READER COMMENTS
If you have a comment you want posted, send to rdavis@africamail.com
WEBPAGE
These updates are also available at www.childsurvival.net
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
40757765 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |